| Symbol | CANF |
|---|---|
| Name | CAN FITE BIOPHARMA LTD |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | BIOMED |
| Address | 26 BEN GURION STREET, RAMAT GAN, 5257346, Israel |
| Telephone | 03-9241114 |
| Fax | 03-9249378 |
| motti@canfite.co.il | |
| Website | www.canfite.com |
| Incorporation | Israel |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | TASE;NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The companys lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fites liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Additional info from NASDAQ: |
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Read morePublication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Read moreCan-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Read moreCan-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Read moreCan-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Read moreCan-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07410455 | An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson i… | Phase2 | Lowe Syndrome | Not_Yet_Recruiting | 2026-06-01 | 2027-08-31 | ClinicalTrials.gov |
| NCT06643260 | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Stu… | Phase3 | Plaque Psoriasis | Not_Yet_Recruiting | 2025-06-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT06387342 | Namodenoson Treatment of Advanced Pancreatic Cancer | Phase2 | Pancreatic Adenocarcinoma | Recruiting | 2024-11-10 | 2026-12-15 | ClinicalTrials.gov |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients W… | Phase3 | Hepatocellular Carcinoma | Recruiting | 2023-03-15 | 2026-10-01 | ClinicalTrials.gov |
| NCT04697810 | Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | Phase2 | NASH - Nonalcoholic Steatohepatitis | Recruiting | 2021-12-10 | 2025-10-15 | ClinicalTrials.gov |
| NCT04333472 | Piclidenoson for Treatment of COVID-19 | Phase2 | COVID-19 | Completed | 2021-01-06 | 2022-04-21 | ClinicalTrials.gov |
| NCT01905124 | Safety &Efficacy of CF101 to Subjects With Uveitis | Phase2 | Uveitis, Posterior | Withdrawn | 2019-01-01 | 2019-10-01 | ClinicalTrials.gov |
| NCT00837291 | A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of … | Phase2 | Osteoarthritis of the Knee | Withdrawn | 2018-11-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT03168256 | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis | Phase3 | Plaque Psoriasis | Completed | 2018-09-15 | 2022-04-27 | ClinicalTrials.gov |
| NCT02927314 | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic F… | Phase2 | Non-alcoholic Steatohepatitis (NASH) | Completed | 2017-11-27 | 2020-03-01 | ClinicalTrials.gov |
| NCT02647762 | CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis | Phase3 | Rheumatoid Arthritis | Terminated | 2017-10-30 | 2020-11-30 | ClinicalTrials.gov |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safet… | Phase2 | Hepatocellular Carcinoma | Completed | 2014-09-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT01265667 | Trial of CF101 to Treat Patients With Psoriasis | Phase2 | Plaque Psoriasis | Completed | 2011-07-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01235234 | Trial of CF101 to Treat Patients With Dry Eye Disease | Phase3 | Keratoconjunctivitis Sicca | Completed | 2011-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01034306 | Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis | Phase2 | Rheumatoid Arthritis | Completed | 2010-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01033422 | Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevate… | Phase2 | Ocular Hypertension | Completed | 2010-10-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT00790673 | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 | Phase1 | Chronic Hepatitis C | Completed | 2009-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | Phase1 | Hepatocellular Carcinoma | Completed | 2009-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00556894 | Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients | Phase2 | Rheumatoid Arthritis | Completed | 2008-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00428974 | Safety and Efficacy Study of CF101 to Treat Psoriasis | Phase2 | Plaque Psoriasis | Completed | 2007-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00349466 | Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca | Phase2 | Keratoconjunctivitis Sicca | Completed | 2007-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00280917 | Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients | Phase2 | Rheumatoid Arthritis | Completed | 2006-06-01 | 2007-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04333472 |
| Piclidenoson | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04333472 |
| Placebo | Other | Phase PHASE2 | Uveitis, Posterior | WITHDRAWN | NCT01905124 |
| CF101 | Other | Phase PHASE2 | Uveitis, Posterior | WITHDRAWN | NCT01905124 |
| Placebo | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02927314 |
| CF102 | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02927314 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT01265667 |
| CF101 | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT01265667 |
| MTX | Other | Phase PHASE3 | Rheumatoid Arthritis | TERMINATED | NCT02647762 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | TERMINATED | NCT02647762 |
| CF101 2 mg | Other | Phase PHASE3 | Rheumatoid Arthritis | TERMINATED | NCT02647762 |
| CF101 1 mg | Other | Phase PHASE3 | Rheumatoid Arthritis | TERMINATED | NCT02647762 |
| Placebo for | Other | Phase PHASE2 | Ocular Hypertension | COMPLETED | NCT01033422 |
| CF101 | Other | Phase PHASE2 | Ocular Hypertension | COMPLETED | NCT01033422 |
| Placebo control | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01034306 |
| CF101 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01034306 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| Apremilast 30mg | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| CF101 3mg | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| CF101 2mg | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| CF101 | Other | Phase PHASE3 | Keratoconjunctivitis Sicca | COMPLETED | NCT01235234 |
| Placebo | Other | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT02128958 |
| CF102 | Other | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT02128958 |
| Placebo | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | RECRUITING | NCT04697810 |
| Namodenoson | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | RECRUITING | NCT04697810 |
| Namodenoson 25mg | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | RECRUITING | NCT06387342 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | NOT_YET_RECRUITING | NCT06643260 |
| piclidenoson | Other | Phase PHASE3 | Plaque Psoriasis | NOT_YET_RECRUITING | NCT06643260 |
| Placebo | Other | Phase PHASE3 | Hepatocellular Carcinoma | RECRUITING | NCT05201404 |
| Namodenoson | Other | Phase PHASE3 | Hepatocellular Carcinoma | RECRUITING | NCT05201404 |
| piclidenoson | DRUG | Phase PHASE3 | Plaque Psoriasis | NOT_YET_RECRUITING | NCT06643260 |
| Namodenoson 25mg | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | RECRUITING | NCT06387342 |
| Namodenoson | DRUG | Phase PHASE3 | Hepatocellular Carcinoma | RECRUITING | NCT05201404 |
| Piclidenoson | DRUG | Phase PHASE2 | Lowe Syndrome | NOT_YET_RECRUITING | NCT07410455 |
| Placebo Oral Tablet | DRUG | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| Apremilast 30mg | DRUG | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| CF101 3mg | DRUG | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| MTX | DRUG | Phase PHASE3 | Rheumatoid Arthritis | TERMINATED | NCT02647762 |
| CF101 2 mg | DRUG | Phase PHASE3 | Rheumatoid Arthritis | TERMINATED | NCT02647762 |
| CF101 1 mg | DRUG | Phase PHASE3 | Rheumatoid Arthritis | TERMINATED | NCT02647762 |
| Placebo control | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01034306 |
| Placebo for | DRUG | Phase PHASE2 | Ocular Hypertension | COMPLETED | NCT01033422 |
| CF 102 | DRUG | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT00790673 |
| CF102 | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02927314 |
| CF101 4mg | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT00428974 |
| CF101 2mg | DRUG | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03168256 |
| CF101 1mg | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT00428974 |
| Placebo | DRUG | Phase PHASE3 | Plaque Psoriasis | NOT_YET_RECRUITING | NCT06643260 |
| CF101 | DRUG | Phase PHASE2 | Uveitis, Posterior | WITHDRAWN | NCT01905124 |